NCT02009410

A Study to Assess the Effect of Creon® on Pancreatic Exocrine Insufficiency in Subjects With Diabetes Mellitus Type 2

A Double-blind, Randomized, Multi-center, Placebo-controlled, Parallel-group Study to Assess the Effect of Creon® on Pancreatic Exocrine Insufficiency in Subjects With Diabetes Mellitus Type 2

• Status: Withdrawn
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Abbott · Industry
• Sex: All
• Age: 30 Years
• Healthy volunteers: Not accepted

Summary

maldigestion of dietary macronutrients (pancreas not producing enough enzymes for digestion of fat, sugars and proteins) in diabetes type II

Conditions

• Exocrine Pancreatic Insufficiency in Subjects With Diabetes Mellitus Type 2

Interventions

Type	Name	Description
DRUG	Creon	Creon 25000 (2 capsules per meal 3 times per day and 1 capsule/snack 2 times per day) during 12 weeks
DRUG	Creon 25000 matching Placebo	Creon 25000 placebo matching capsules (2 capsules per meal 3 times per day and 1 capsule/snack 2 times per day) during 12 weeks

Timeline

• Start date: 2013-11-01
• Primary completion: 2014-08-01
• Completion: 2014-08-01
• First posted: 2013-12-12
• Last updated: 2014-06-20

Locations

10 sites across 2 countries: Germany, Spain